Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fumoleau

Showing results (21-30 of 110) with videos related to

Pageof 11
Sort By:
The Oncologist|January 7, 2015
Role of positron emission tomography for the monitoring of response to therapy in breast cancerOlivier Humbert, Alexandre Cochet, Bruno Coudert, et al.
Anti-Cancer Drugs|September 10, 2015
Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendationsXavier Pivot, Gilles Aulagner, Jean Yves Blay, et al.
Bulletin Du Cancer|January 7, 2004
[Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer]Mario Campone, Pierre Kerbrat, Henri Roché, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 29, 2005
Adaptation and performance of an immuno-PCR assay for the quantification of Aviscumine in patient plasma samplesMichael Adler, Martin Langer, Klaus Witthohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cellsSylvain Ladoire, Laurent Arnould, Lionel Apetoh, et al.
Bulletin Du Cancer|May 30, 2012
Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-upThomas Filleron, Andrew Kramar, Florence Dalenc, et al.
Bulletin Du Cancer|March 13, 2016
[CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3]Jean-Marc Riedinger, Vincent Goussot, Isabelle Desmoulins, et al.
Clinical Breast Cancer|July 9, 2011
Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 yearsSylvain Ladoire, Laurie Rambach, Valérie Quipourt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumorsChristian Dittrich, Herlinde Dumez, Hilary Calvert, et al.
Bulletin Du Cancer|November 1, 2006
Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trialMichel Héry, Jacques Bonneterre, Henri Roché, et al.
Pageof 11

Showing results (21-30 of 110) with videos related to

Sort By:
Pageof 11
The Oncologist|January 7, 2015
Role of positron emission tomography for the monitoring of response to therapy in breast cancerOlivier Humbert, Alexandre Cochet, Bruno Coudert, et al.
Anti-Cancer Drugs|September 10, 2015
Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendationsXavier Pivot, Gilles Aulagner, Jean Yves Blay, et al.
Bulletin Du Cancer|January 7, 2004
[Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer]Mario Campone, Pierre Kerbrat, Henri Roché, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 29, 2005
Adaptation and performance of an immuno-PCR assay for the quantification of Aviscumine in patient plasma samplesMichael Adler, Martin Langer, Klaus Witthohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cellsSylvain Ladoire, Laurent Arnould, Lionel Apetoh, et al.
Bulletin Du Cancer|May 30, 2012
Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-upThomas Filleron, Andrew Kramar, Florence Dalenc, et al.
Bulletin Du Cancer|March 13, 2016
[CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3]Jean-Marc Riedinger, Vincent Goussot, Isabelle Desmoulins, et al.
Clinical Breast Cancer|July 9, 2011
Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 yearsSylvain Ladoire, Laurie Rambach, Valérie Quipourt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumorsChristian Dittrich, Herlinde Dumez, Hilary Calvert, et al.
Bulletin Du Cancer|November 1, 2006
Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trialMichel Héry, Jacques Bonneterre, Henri Roché, et al.
Pageof 11